PAION AG Release: Recruitment of Phase II/III Study With Short-Acting Anaesthetic/Sedative Remimazolam (Ono's Development Code: ONO-2745) in Japan is Completed

Published: May 08, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Aachen (Germany), 08 May 2013 - The biopharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, General Standard: PA8) today announces that its partner, Ono Pharmaceutical Co., Ltd. ('ONO') has published, that the recruitment of the Phase II/III study with Remimazolam for general anaesthesia is completed. Remimazolam was administered during anaesthesia to 375 surgery patients.

Help employers find you! Check out all the jobs and post your resume.

Back to news